GLP-3 refers to next-generation triple-agonist peptides that simultaneously target GLP-1, GIP, and glucagon receptors. This advanced compound is researched for superior metabolic effects, including powerful appetite suppression, accelerated fat loss, enhanced glycemic control, and significant weight reduction (with clinical data showing up to ~24% body weight loss in studies). It represents the cutting edge in obesity and metabolic research, offering broader benefits than single or dual agonists for energy balance, fat metabolism, and overall weight management.